The Capital Markets Matchmaker

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is pleased to participate in the Second Annual Centri Business Consulting, LLC Conference, taking place Tuesday, April 14, 2026, at Nasdaq MarketSite in New York City.

The Centri Capital Conference is a B2i Digital Featured Conference. See more details at: https://b2idigital.com/centri-capital-conference-2026

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage pharmaceutical company built around JOTROL, a patented resveratrol formulation that has demonstrated materially higher bioavailability than earlier versions of the compound. Based in Jupiter, Florida, the company operates a dual-path business model: advancing a therapeutic pipeline targeting neuroinflammation and central nervous system disorders while commercializing Nugevia, a premium longevity supplement line using the same delivery technology. On the pharmaceutical side, the FDA cleared the company's IND application in November 2025, authorizing a Phase 2A clinical trial in Parkinson's disease. The company is also exploring potential applications in Alzheimer's disease, Friedreich's Ataxia, Mucopolysaccharidoses Type I, and MELAS. Jupiter's consumer business launched in 2025 with three Nugevia products (GLO, PWR, and MND), each targeting pillars of healthy aging. Jupiter completed its IPO in December 2024 and is led by Christer Rosén, Founder, Chairman, and CEO.

Building on a successful inaugural year, the Centri Capital Conference returns as a premier one-day event bringing together 500+ institutional investors, industry leaders, and executives from over 50 participating companies across healthcare, life sciences, technology, AI, digital assets, fintech, and other high-growth sectors. The full-day program features company presentations, fireside chats, curated one-on-one investor meetings, and a networking reception.

B2i Digital is working closely with the Centri Business Consulting team, including Michael Aiello, Amanda Zeigler, Gerald Wik, Stephan Parico, Christopher Mora, Jaime Krug, Adam Batchelor, David Lawlor, and Dale Jones to enhance each presenter's reach through B2i Digital's network of 1.5M+ investors.

The Centri Capital Conference is an invite-only event. For more information and to request registration, visit: https://www.meetmax.com/sched/event_130523/conference_register.html?attendee_role_id=CENTRI_INVESTOR

Learn more about Jupiter Neurosciences, Inc. at https://b2idigital.com/jupiter-neurosciences-1?hsLang=en.

Content is for informational purposes only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

As Marketing Partner for the Second Annual Centri Capital Conference, @B2i Digital, Inc. thanks Nelson Mullins for its support as a Promotional Sponsor, helping bring together growth company executives, institutional investors, and capital markets participants for this premier event at Nasdaq MarketSite in New York City. The Centri Capital Conference is a B2i Digital Featured Conference. See more details at: https://b2idigital.com/centri-capital-conference-2026 Nelson Mullins is your go-to law firm for IPOs, secondary offerings, ATMs, SPACs, RTOs and all things securities. With over 1,000 professionals across the United States, Nelson Mullins is your full service legal partner. Nelson Mullins is represented by David Mannheim and Mike Bradshaw. Learn more about Nelson Mullins at https://www.nelsonmullins.com/. Building on a successful inaugural year, the Centri Capital Conference returns as a premier one-day, invite-only event bringing together 500+ institutional investors, industry leaders, and executives from 50+ companies across healthcare, life sciences, technology, AI, digital assets, fintech, and other high-growth sectors. Programming includes company presentations, fireside chats, curated one-on-one investor meetings, and a networking reception. B2i Digital is working closely with the Centri Business Consulting team, including Michael M. Aiello, CPA, Amanda Zeigler, Gerald Wik, CPA, Stephan P., Christopher Mora, CPA, Jaime Krug, CPA, Adam Batchelor, David Lawlor, and Dale L. Jones to enhance each sponsor's reach through B2i Digital's network of 1.5M+ capital market decision markers. Register for the Centri Capital Conference: https://www.meetmax.com/sched/event_130523/conference_register.html Content is for informational purposes only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is pleased to participate in the Second Annual Centri Capital Conference, taking place Tuesday, April 14, 2026, at Nasdaq MarketSite in New York City. The Centri Capital Conference is a @B2i Digital, Inc. Featured Conference. See more details at: https://b2idigital.com/centri-capital-conference-2026 Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage pharmaceutical company built around JOTROL, a patented resveratrol formulation that has demonstrated materially higher bioavailability than earlier versions of the compound. Based in Jupiter, Florida, the company operates a dual-path business model: advancing a therapeutic pipeline targeting neuroinflammation and central nervous system disorders while commercializing Nugevia, a premium longevity supplement line using the same delivery technology. On the pharmaceutical side, the FDA cleared the company's IND application in November 2025, authorizing a Phase 2A clinical trial in Parkinson's disease. The company is also exploring potential applications in Alzheimer's disease, Friedreich's Ataxia, Mucopolysaccharidoses Type I, and MELAS. Jupiter's consumer business launched in 2025 with three Nugevia products (GLO, PWR, and MND), each targeting pillars of healthy aging. Jupiter completed its IPO in December 2024 and is led by Christer Rosén, Founder, Chairman, and CEO. Building on a successful inaugural year, the Centri Capital Conference returns as a premier one-day event bringing together 500+ institutional investors, industry leaders, and executives from over 50 participating companies across healthcare, life sciences, technology, AI, digital assets, fintech, and other high-growth sectors. The full-day program features company presentations, fireside chats, curated one-on-one investor meetings, and a networking reception. B2i Digital is working closely with the Centri Business Consulting team, including Michael Aiello, Amanda Zeigler, Gerald Wik, Stephan Parico, Christopher Mora, Jaime Krug, Adam Batchelor, David Lawlor, and Dale Jones to enhance each presenter's reach through B2i Digital's network of 1.5M+ investors. The Centri Capital Conference is an invite-only event. For more information and to request registration, visit: https://www.meetmax.com/sched/event_130523/conference_register.html?attendee_role_id=CENTRI_INVESTOR Learn more about Jupiter Neurosciences, Inc. at https://b2idigital.com/jupiter-neurosciences-1?hsLang=en. Content is for informational purposes only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

eXoZymes Inc. (Nasdaq: EXOZ) is pleased to participate in the Second Annual @centribusinessconsulting Capital Conference, taking place Tuesday, April 14, 2026, at @nasdaq MarketSite in New York City.

The Centri Capital Conference is a @b2idigital Featured Conference. See more details at: https://b2idigital.com/centri-capital-conference-2026

eXoZymes Inc. (Nasdaq: EXOZ) is a biotechnology company that has developed a new way to produce chemicals without using living cells. The company's technology, called "exozymes," combines enzymes (proteins that speed up chemical reactions) with artificial intelligence to create a manufacturing platform that transforms biomass into chemicals, medicines, and fuels. Unlike traditional synthetic biology that relies on living cells, eXoZymes' cell-free approach operates more like industrial chemistry, avoiding the common problems that prevent biological manufacturing from reaching commercial scale.

Building on a successful inaugural year, the Centri Capital Conference returns as a premier one-day event bringing together 500+ institutional investors, industry leaders, and executives from over 50 participating companies across healthcare, life sciences, technology, AI, digital assets, fintech, and other high-growth sectors. The full-day program features company presentations, fireside chats, curated one-on-one investor meetings, and a networking reception.

B2i Digital is working closely with the Centri Business Consulting team, including Michael Aiello, Amanda Zeigler, Gerald Wik, Stephan Parico, Christopher Mora, Jaime Krug, Adam Batchelor, David Lawlor, Nikki Frazier, and Dale Jones to enhance each presenter's reach through B2i Digital's network of 1.5M+ investors.

The Centri Capital Conference is an invite-only event. For more information and to request registration, visit: https://www.meetmax.com/sched/event_130523/conference_register.html?attendee_role_id=CENTRI_INVESTOR

Learn more about eXoZymes Inc. at https://b2idigital.com/exozymes-1?hsLang=en.

Content is for informational purposes only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

As Marketing Partner for the Second Annual Centri Capital Conference, B2i Digital thanks Aon plc for its support as a Promotional Sponsor, helping bring together growth company executives, institutional investors, and capital markets participants for this premier event at Nasdaq MarketSite in New York City.

The Centri Capital Conference is a B2i Digital Featured Conference.

As Marketing Partner for the Second Annual Centri Capital Conference, @b2idigital thanks Churchwell Insurance for its support as a Bronze Sponsor, helping bring together growth company executives, institutional investors, and capital markets participants for this premier event at https://t.co/a3LfygejYD

eXoZymes Inc. (Nasdaq: EXOZ) is pleased to participate in the Second Annual Centri Capital Conference, taking place Tuesday, April 14, 2026, at Nasdaq MarketSite in New York City. The Centri Capital Conference is a @B2i Digital, Inc. Featured Conference. See more details at: https://b2idigital.com/centri-capital-conference-2026 eXoZymes Inc. (Nasdaq: EXOZ) is a biotechnology company that has developed a new way to produce chemicals without using living cells. The company's technology, called "exozymes," combines enzymes (proteins that speed up chemical reactions) with artificial intelligence to create a manufacturing platform that transforms biomass into chemicals, medicines, and fuels. Unlike traditional synthetic biology that relies on living cells, eXoZymes' cell-free approach operates more like industrial chemistry, avoiding the common problems that prevent biological manufacturing from reaching commercial scale. Building on a successful inaugural year, the Centri Capital Conference returns as a premier one-day event bringing together 500+ institutional investors, industry leaders, and executives from over 50 participating companies across healthcare, life sciences, technology, AI, digital assets, fintech, and other high-growth sectors. The full-day program features company presentations, fireside chats, curated one-on-one investor meetings, and a networking reception. B2i Digital is working closely with the Centri Business Consulting team, including Michael Aiello, Amanda Zeigler, Gerald Wik, Stephan Parico, Christopher Mora, Jaime Krug, Adam Batchelor, David Lawlor, Nikki Frazier, and Dale Jones to enhance each presenter's reach through B2i Digital's network of 1.5M+ investors. The Centri Capital Conference is an invite-only event. For more information and to request registration, visit: https://www.meetmax.com/sched/event_130523/conference_register.html?attendee_role_id=CENTRI_INVESTOR Learn more about eXoZymes Inc. at https://b2idigital.com/exozymes-1?hsLang=en. Content is for informational purposes only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

As Marketing Partner for the Second Annual Centri Business Consulting, LLC Capital Conference, B2i Digital thanks Aon plc for its support as a Promotional Sponsor, helping bring together growth company executives, institutional investors, and capital markets participants for this premier event at Nasdaq MarketSite in New York City.

The Centri Capital Conference is a B2i Digital Featured Conference. See more details at: https://b2idigital.com/centri-capital-conference-2026

Aon plc (NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Through actionable analytic insight, globally integrated Risk Capital and Human Capital expertise, and locally relevant solutions, our colleagues provide clients in over 120 countries with the clarity and confidence to make better risk and people decisions that protect and grow their businesses.

Aon plc is represented by Dan Blaine and Thomas Stenberg.

Learn more about Aon plc at https://www.aon.com/en/.

Building on a successful inaugural year, the Centri Capital Conference returns as a premier one-day, invite-only event bringing together 500+ institutional investors, industry leaders, and executives from 50+ companies across healthcare, life sciences, technology, AI, digital assets, fintech, and other high-growth sectors. Programming includes company presentations, fireside chats, curated one-on-one investor meetings, and a networking reception.

B2i Digital is working closely with the Centri Business Consulting team, including Michael M. Aiello, CPA, Amanda Zeigler, Gerald Wik, CPA, Stephan P., Christopher Mora, CPA, Jaime Krug, CPA, Adam Batchelor, David Lawlor, and Dale L. Jones to enhance each presenter's reach through B2i Digital's network of 1.5M+ investors.

Register for the Centri Capital Conference: https://www.meetmax.com/sched/event_130523/conference_register.html

Content is for informational purposes only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is pleased to participate in the Second Annual Centri Capital Conference, taking place Tuesday, April 14, 2026, at Nasdaq MarketSite in New York City. The Centri Capital Conference is a @B2i Digital, Inc. Featured Conference. See more details at: https://b2idigital.com/centri-capital-conference-2026 Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biopharmaceutical company developing cancer treatments using its proprietary INTASYL®️ technology, a patented form of siRNA (short interfering RNA) gene silencing that works by silencing specific genes that allow tumors to evade the immune system. Rather than attacking cancer cells directly, INTASYL reactivates the body's own T cells, a type of immune cell, so they can more effectively identify and kill tumors. Phio's lead program, PH-762, targets the PD-1 gene in skin cancer and completed the treatment phase of a Phase 1b clinical trial in January 2026, with 22 patients treated across five escalating dose cohorts. A second program, PH-894, targets the BRD4 gene across a broader range of cancers and has completed the studies required to file for FDA clearance to begin clinical testing. Phio holds 59 issued patents with protection extending to 2044 and carries no debt. Building on a successful inaugural year, the Centri Capital Conference returns as a premier one-day event bringing together 500+ institutional investors, industry leaders, and executives from over 50 participating companies across healthcare, life sciences, technology, AI, digital assets, fintech, and other high-growth sectors. The full-day program features company presentations, fireside chats, curated one-on-one investor meetings, and a networking reception. B2i Digital is working closely with the Centri Business Consulting team, including Michael Aiello, Amanda Zeigler, Gerald Wik, Stephan Parico, Christopher Mora, Jaime Krug, Adam Batchelor, David Lawlor, and Dale Jones to enhance each presenter's reach through B2i Digital's network of 1.5M+ investors. The Centri Capital Conference is an invite-only event. For more information and to request registration, visit: https://www.meetmax.com/sched/event_130523/conference_register.html?attendee_role_id=CENTRI_INVESTOR Learn more about Phio Pharmaceuticals Corp. at https://b2idigital.com/phio-pharmaceuticals-corp-1?hsLang=en. Content is for informational purposes only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

In a recent article, eXoZymes (Nasdaq: EXOZ) was featured in The Village Voice for its work on NCT (N-trans-Caffeoyltyramine), a naturally occurring molecule at the center of a growing scientific conversation about metabolic health beyond GLP-1 weight-loss drugs.

eXoZymes is a B2i Digital Featured Company. See their full profile at https://b2idigital.com/exozymes-1.

eXoZymes has developed cell-free biomanufacturing methods capable of producing high-purity NCT at scale, turning a molecule once found only in trace amounts in peppercorns (roughly 0.0014 percent concentration) into one that can now be explored in depth. The article places that capability in the context of a broader shift in metabolic health research, where scientists are looking past appetite suppression toward approaches that address how the body burns energy at the cellular level.

With over 1.4 billion people worldwide affected by obesity, diabetes, and metabolic dysfunction, the interest is growing. Preclinical research published in Nature Cell Death & Disease showed a roughly 30 percent reduction in weight gain in mouse models on a high-fat diet receiving NCT, with no change in food intake. While further studies are required before conclusions about human health can be drawn, the Village Voice piece places eXoZymes squarely at the forefront of the ongoing effort to produce the NCT molecule at scale.

Read the complete article: https://www.villagevoice.com/the-metabolic-engine-how-scientists-are-exploring-a-new-path-beyond-glp-1-weight-loss-drugs/

eXoZymes is a Los Angeles, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals. The company’s proprietary exozyme platform offers a scalable, eco-friendly alternative to traditional petrochemical processes, with technology validated through publications in Nature Communications and Nature Chemical Biology. Recently demonstrating gram-scale production of NCT with over 99% purity in just five months, eXoZymes focuses on high-value products including active pharmaceutical ingredients, nutraceuticals, and sustainable aviation fuel.

eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff.

Learn more about eXoZymes Inc. at https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor and learn about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies.

Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) announced that the company has appointed Kristopher Fishman and Sanjiv Lal to the Nugevia™ Advisory Board. The two bring direct distribution relationships across compounding pharmacies and wellness channels, an addressable market the Company estimates at over $1.5 billion in combined U.S. nutraceutical sales. Jupiter Neurosciences is a B2i Digital Featured Company. Learn more at https://b2idigital.com/jupiter-neurosciences-1. Fishman is CEO and President of Wells Pharmacy Network, LLC, a privately held nationwide compounding pharmacy licensed in 48 states. Lal is a healthcare entrepreneur with more than two decades of experience across biotechnology, laboratory systems, and regenerative medicine, and is Co-Founder and Partner at both Motivant and RegenTherapy. #stocks #investing #stocktok “Kris and Sanjiv each bring deep, hands-on experience in the channels where we see the strongest natural demand for Nugevia™,” said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “Compounding pharmacies and wellness centers are staffed by practitioners who evaluate formulation science before recommending products to their patients and clients. That is precisely the kind of environment where JOTROL’s published bioavailability data and its efficacy profile in addressing inflammation and mitochondrial function are most relevant.” Read the full press release: https://jupiterneurosciences.com/press-releases/?i=163842 Nugevia™ is Jupiter’s consumer longevity product line, powered by the same proprietary JOTROL™ micellar delivery technology that underpins the Company’s clinical pipeline, including a Phase IIa clinical trial in Parkinson’s disease that has received FDA clearance. The product line currently includes three formulations: PWR (mitochondrial support), MND (cognitive health), and GLO (skin vitality). Products are available direct-to-consumer at www.nugevia.com, and the Company is now expanding into practitioner-led channels where the formulations’ clinical-grade bioavailability profile can be a differentiator. Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison Silva, President and CBO; Saleem Elmasri, CPA, CFO; and Marsh Hayward, Ph.D., Co-Founder and CSO. To learn more about the company, visit www.jupiterneurosciences.com. For investor inquiries, or to arrange a meeting with Jupiter’s executive team, contact ir@jupiterneurosciences.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.##

@phiopharmaceuticals Corp. (Nasdaq: PHIO) is pleased to participate in the Second Annual @centriconsulting Conference, taking place Tuesday, April 14, 2026, at @nasdaq MarketSite in New York City.

The Centri Capital Conference is a @b2i_digital Featured Conference. See more details at: https://b2idigital.com/centri-capital-conference-2026

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biopharmaceutical company developing cancer treatments using its proprietary INTASYL® technology, a patented form of siRNA (short interfering RNA) gene silencing that works by silencing specific genes that allow tumors to evade the immune system. Rather than attacking cancer cells directly, INTASYL reactivates the body's own T cells, a type of immune cell, so they can more effectively identify and kill tumors. Phio's lead program, PH-762, targets the PD-1 gene in skin cancer and completed the treatment phase of a Phase 1b clinical trial in January 2026, with 22 patients treated across five escalating dose cohorts. A second program, PH-894, targets the BRD4 gene across a broader range of cancers and has completed the studies required to file for FDA clearance to begin clinical testing. Phio holds 59 issued patents with protection extending to 2044 and carries no debt.

Building on a successful inaugural year, the Centri Capital Conference returns as a premier one-day event bringing together 500+ institutional investors, industry leaders, and executives from over 50 participating companies across healthcare, life sciences, technology, AI, digital assets, fintech, and other high-growth sectors. The full-day program features company presentations, fireside chats, curated one-on-one investor meetings, and a networking reception.

B2i Digital is working closely with the Centri Business Consulting team, including Michael M. Aiello, CPA, Amanda Zeigler, Gerald Wik, CPA, Stephan P., Christopher Mora, CPA, Jaime Krug, CPA, Adam Batchelor, David Lawlor, and Dale L. Jones to enhance each presenter's reach through B2i Digital's network of 1.5M+ investors.

As Marketing Partner for the Second Annual Centri Capital Conference, B2i Digital thanks ROTH Capital Partners LLC for its support as a Silver Sponsor, helping bring together growth company executives, institutional investors, and capital markets participants for this premier event at Nasdaq MarketSite in New York City.

The Centri Capital Conference is a B2i Digital Featured Conference. See more details at: https://b2idigital.com/centri-capital-conference-2026

Roth Capital Partners, LLC ("ROTH") is a relationship-driven investment bank focused on serving growth companies and their investors. Our full service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Hea